# A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors

> **NCT04671901** · PHASE2 · TERMINATED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 2 (actual)

## Conditions studied

- Solid Tumor
- Solid Tumor, Childhood
- Solid Carcinoma

## Interventions

- **DRUG:** Romiplostim

## Key facts

- **NCT ID:** NCT04671901
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-10
- **Primary completion:** 2023-03-29
- **Final completion:** 2023-03-29
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Lack of accrual
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04671901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04671901, "A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04671901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*